scholarly journals Detection of Coccidian Parasites and their Clinical Manifestation, Treatment and Prophylaxis in HIV Infected Patients in Tribhuvan University Teaching Hospital

1970 ◽  
Vol 8 (8) ◽  
pp. 51-55 ◽  
Author(s):  
A Basnet ◽  
BB Sherchan ◽  
B Rijal ◽  
S Sharma ◽  
P Khadga
Keyword(s):  
Clinical Manifestation ◽  
Teaching Hospital ◽  
Opportunistic Infections ◽  
Previous History ◽  
University Teaching ◽  
Hiv Patients ◽  
Cryptosporidium Spp ◽  
Long Term Treatment ◽  
Coccidian Parasites

The objective was to know the prevalence of coccidian parasites, their clinical manifestation, treatment and prophylaxis in HIV infected patients in Tribhuvan University Teaching Hospital, Nepal.A total of 300 stool samples from 128 (64.00%) HIV patient without previous history of treatment with antiretroviral therapy (ART), 72 (36.00%) under ART treatment and 100 HIV seronegative control samples were collected and examined by wet mount, Kinyoun modified Ziehl Neelsen staining, Sheather's sucrose flotation and modified formalin-ethyl acetate sedimentation methods.The coccidian parasites were detected in 22 (11.0%) of the 200 HIV infected patients, 18 (9.0%) without ART and 4 (2.0%) with ART undertaking patients. Those without ART had majority of 11 (8.5%) Cryptosporidium spp and those with ART had equal percentage of 2 (0.03%) Cryptosporidium spp and 2 (0.03%) Cyclospora spp. The prevalence of coccidian parasites was significantly higher in patients with diarrhea (20/22) than in those without diarrhea (2/22) (P value < 0.05). The drug therapy indices of the antibiotic, Cotrimoxazole given for 30 days in combination with ART for treatment and/or prophylaxis for opportunistic infections showed that long term treatment was needed for the clearance of coccidian parasites. Among 8 Cyclospora identified, 7.6% cleared from stool anlaysis after 30th days of treatment likewise 15.3% of Cryptosporidium cleared after 45th days of treatment.In conclusion, Cryptosporidium followed by Cyclospora appeared to be the predominant coccidian parasite associated with diarrhea among HIV patients. Clinicians are requested to query for coccidian parasites to evaluate diarrhea in HIV patients. Cotrimoxazole is the drug of choice in curing coccidian parasites. So, it should be given along with ART as a treatment and/ or prophylaxis that act against both opportunistic infections as well as coccidian parasites. However its side effects should be evaluated for its long term prophylaxis. Key words: AIDS; Coccidian; Diarrhea; HIV; ART; OIs. DOI: 10.3126/sw.v8i8.3849 Scientific World Vol.8(8) 2010 pp.51-55  

Hepatic histopathological findings in HIV patients at postmortem in Jos university teaching hospital, Nigeria

2006 ◽  
Vol 36 (4) ◽  
pp. 228-231 ◽  
Author(s):  
Godwins O Echejoh ◽  
Barnabas M Mandong ◽  
Matthew N Tanko ◽  
Agabus N Manasseh ◽  
Edith N Okeke ◽  
...  
Keyword(s):  
Teaching Hospital ◽  
University Teaching ◽  
Hiv Patients ◽  
Histopathological Findings

Evaluation of microalbumin, cystatin c, creatinine and uric acid levels in HIV patients in Nnamdi Azikiwe University Teaching Hospital, Nnewi

2021 ◽  
Vol 8 (3) ◽  
pp. 132-142
Author(s):  
Ezeugwunne Ifeoma Priscilla ◽  
Amaifeobu Clement ◽  
Meludu Samuel Chukwuemeka ◽  
Analike Rosemary Adamma ◽  
Nnamdi Johnjude Chinonso ◽  
...  
Keyword(s):  
Uric Acid ◽  
Cystatin C ◽  
Teaching Hospital ◽  
University Teaching ◽  
Hiv Positive ◽  
Hiv Patients ◽  
Voluntary Counseling And Testing ◽  
Group B ◽  
And Control ◽  
Hiv Negative

This study evaluated the microalbumin, cystatin C, creatinine and uric acid levels in HIV patients in Nnamdi Azikiwe University Teaching Hospital, Nnewi (NAUTH). A total of one hundred (100) male and female HIV positive and control participants who were aged between 18 and 60 years attending the voluntary counseling and testing unit (VCT) and antiretroviral therapy unit (ART) of NAUTH were randomly recruited for the study and grouped thus: Group A (HIV positive symptomatic participants on long term ART (HPSPLTART) (n= 25); Group B (HIV positive symptomatic participants on short term ART (HPSPSTART) (n= 25); Group C: Asymptomatic HIV positive participants NOT on ART (AHPPNART) (n=25) and Group D: control (n=25).6mls of blood sample and 10mls of freshly voided urine samples were collected from each of the participants for the evaluation of biochemical parameters using standard laboratory methods. Results showed significantly higher BMI and SBP in HPSPSTART than in control (p=0.04; 0.02). SBP was significantly higher in HPSPLTART than in AHPPNART and Control (p=0.00). DBP was significantly higher in HPSPLTART than in HPSPSTART and control respectively (p=0.00). There were significantly higher plasma creatinine and Cys-C levels in both male HIV positives and male HIV positive participants on ART than in both females respectively (p0.00; 0.02). Also, BMI, creatinine, uric acid and Cystatin C levels were significantly higher in male HIV negative participants than in female HIV negative participants (p=0.00; 0.04; 0.02; 0.01). This study has revealed greater risk for renal disease among the HIV participants studied.

scholarly journals Mitochondrial and Oxidative Impacts of Short and Long-term Administration of HAART on HIV Patients

2020 ◽  
Vol 15 (2) ◽  
pp. 110-124
Author(s):  
Joy E. Ikekpeazu ◽  
Oliver C. Orji ◽  
Ikenna K. Uchendu ◽  
Lawrence U.S. Ezeanyika
Keyword(s):  
Treatment Group ◽  
Term Treatment ◽  
Short Term ◽  
Short Term Treatment ◽  
Hiv Patients ◽  
Long Term Treatment ◽  
Term Administration ◽  
Short And Long Term ◽  
One Year

Background and Objective: There may be a possible link between the use of HAART and oxidative stress-related mitochondrial dysfunction in HIV patients. We evaluated the mitochondrial and oxidative impacts of short and long-term administration of HAART on HIV patients attending the Enugu State University Teaching (ESUT) Hospital, Enugu, Nigeria following short and long-term therapy. Methods: 96 patients categorized into four groups of 24 individuals were recruited for the study. Group 1 comprised of age-matched, apparently healthy, sero-negative individuals (the No HIV group); group 2 consisted of HIV sero-positive individuals who had not started any form of treatment (the Treatment naïve group). Individuals in group 3 were known HIV patients on HAART for less than one year (Short-term treatment group), while group 4 comprised of HIV patients on HAART for more than one year (Long-term treatment group). All patients were aged between 18 to 60 years and attended the HIV clinic at the time of the study. Determination of total antioxidant status (TAS in nmol/l), malondialdehyde (MDA in mmol/l), CD4+ count in cells/μl, and genomic studies were all done using standard operative procedures. Results: We found that the long-term treatment group had significantly raised the levels of MDA, as well as significantly diminished TAS compared to the Short-term treatment and No HIV groups (P<0.05). In addition, there was significantly elevated variation in the copy number of mitochondrial genes (mtDNA: D-loop, ATPase 8, TRNALEU uur) in the long-term treatment group. Interpretation and Conclusion: Long-term treatment with HAART increases oxidative stress and causes mitochondrial alterations in HIV patients.

scholarly journals SEMEN ANALYSIS OF INFERTILE NIGERIAN MALES IN SOKOTO STATE NORTH WESTERN NIGERIA.

2013 ◽  
Vol 1 (1) ◽  
Author(s):  
Yusuf TS ◽  
Panti AA ◽  
Ekele BA ◽  
Nwobodo EI
Keyword(s):  
Male Infertility ◽  
Teaching Hospital ◽  
Sperm Count ◽  
Previous History ◽  
University Teaching ◽  
High Rate ◽  
Semen Parameters ◽  
P Value ◽  
Unprotected Sexual Intercourse ◽  
Tract Infections

Background: Male infertility can occur when sperms are limited innumber or function. Infertility is a socially destabilizing and stigmatizing condition for couples but in our society many erroneously believe it is a problem from the female alone. Objectives: To evaluate the semen of infertilemale partners of couplesattending gynaecological clinic of Usmanu Danfodiyo University Teaching Hospital (UDUTH), Sokoto. Methodology: This was a prospective study conducted at the gynaecological clinic of Usmanu Danfodiyo University Teaching Hospital Sokoto between 1stJanuary 2011 and 30th June 2011. For the purpose of this study all male partners of women who complained of inability to conceive after a period of a year or more of unprotected sexual intercourse were recruited into the study. Data was extracted and analyzed using SPSS (version 11). A P–value of less than 0.05 was considered significant. Results: There were 125 cases of male infertility recruited during the period. Majority of the male patients (51.2%) were aged 40 years and above. Considerable percentage of the patients (46.4%) presented with duration of Infertility of 5 years and above. The identified risk factors were a previous history of Urethral discharge (37.6%) and previous treatment of sexually transmitted infections (29.6%). Hypospermia (33%) and Asthenospermia (42.4%) were the commonest disorders of semen Parameters seen. Low sperm count was seen in (36.8%) of studysubjects, Azoospermia was observed in 8% while 16% of them had disorder of sperm morphology. Conclusion: The study shows that infertility is associated with relatively high rate of abnormal sperm volume, motility and count. In addition, genital tract infections are major associated factors. Therefore, efforts to address STIs through primary, secondary and tertiary preventive measures may make significant contributions to reducing the prevalence of male infertility in Sokoto State.

Treatment of Newly Diagnosed, Inner-City Multiple Myeloma Patients with Zoledronate, Dexamethasone, and Low-Dose Thalidomide: A Phase II Trial.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 5124-5124
Author(s):  
Uwe Klueppelberg ◽  
Eric L.P. Smith ◽  
Marc J. Braunstein ◽  
David Kahn ◽  
Olcay A. Batuman
Keyword(s):  
Multiple Myeloma ◽  
Partial Response ◽  
Inner City ◽  
Phase Ii ◽  
Low Dose ◽  
Phase Ii Trial ◽  
Newly Diagnosed ◽  
Hiv Patients ◽  
Long Term Treatment

Abstract Background: This Phase II trial was designed to assess the long-term effectiveness and safety of low-dose thalidomide with dexamethasone and zoledronate (TDZ) in newly diagnosed multiple myeloma (MM) in an inner-city population in which AIDS is the third-leading cause of death. Although the incidence of MM is increased in HIV+ patients, guidelines for treatment of MM in this population are not yet known. The TDZ regimen was intended to be non-myelotoxic and compatible with HAART. Because zoledronate mitigates tumor growth and angiogenesis as well as bone resorption, it was expected to boost the therapeutic effect of thalidomide and dexamethasone. Method:Of 45 consecutive enrollees, 38 (27F/11M; median age = 60.4 years) were evaluable. All patients had skeletal involvement of varying severity; baseline levels of *2-microglobulin (4.3 mg/dL; SE = 0.68) and serum albumin (3.3 mg/dL; S.E.= 0.38) indicated advanced disease. Eight evaluable patients (21%) were HIV+ (7F/1M; median age = 47 years). Patients with HIV were younger (P &lt; .001), with marginally higher *2-microglobulin levels (P = .076). Seven of the HIV+ patients were on HAART at the time of treatment. The TDZ regimen, given for 24 months or until progression, consisted of: thalidomide, 100 mg daily; dexamethasone, 10–40 mg for 4 days/week for 3 weeks each month for 6 months, then reduced to 4 days each month; zoledronate, 4 mg IV monthly; and ASA, 81 mg daily. Response was stratified by reduction of M protein levels: &gt; 75% (very good partial response [VPR]), &gt; 50–75% (partial response [PR]), or 25–50% (minor response [MR]). Results: Age-adjusted one-year survival was 74.4%, and is identical to NCI SEER data (73.7%). Mean duration of TDZ treatment was 21.4 months (range = 13–24). VPR was achieved in 32% (n = 12), PR in 39% (n = 15), and MR in 18% (n = 7). Three patients had stable disease, and one progressed. Median time to maximum response was 3.0 months. Overall cumulative survival at 24 months was 68% by Kaplan-Meier analysis, and was not affected by HIV status, age, or sex. Baseline creatinine clearance both for HIV+ and HIV− patients was within normal limits, and was not adversely affected by monthly treatment with zoledronate (P &gt; .2 for both). Despite prophylactic ASA, thromboembolism occurred in 6 patients (16%), all of whom were successfully treated with full anticoagulation. Other toxicities ≥ Grade 2, were not observed. Skeletal events occurred in 8% of patients; osteonecrosis of the jaw was not encountered. Death occurred in 10 patients, 9 of whom were evaluable; 6 deaths were due to progression or complications of MM, and 4 were from unrelated causes. Seven patients were dropped from the study (5 moved from the area and 2 patients declined to continue). Conclusion: Thalidomide administered at less than half the standard sage in combination with zoledronate and dexamethasone provided safe and effective long-term treatment of MM both in HIV− and HIV+ patients. The modest frequency of toxicity and skeletal events under this regimen indicates improvement in quality of life as well as survival.

Sign in / Sign up

Export Citation Format

Share Document